Artificial Intelligence Archives - Page 5 of 14

Top five most perpetuated AI myths, debunked

Artificial Intelligence, Coronavirus Disease 2019 (COVID-19), Data, Departments, Issue Archives, June 2021, Med Ad News, Sales & Marketing

It is scientifically proven that teenagers are clumsy. The main reason teens are so awkward is that they are growing fast – for example, a 13-year-old’s legs can grow one centimeter a month! The brain must continuously recalibrate precise calculations about movements, and when it misfires, teens stumble. Similarly, COVID-19 caused a sudden growth spurt for Artificial Intelligence (AI) technology in commercial life sciences. And like the newfound height and strength of a growing teenager, AI may feel all “arms and legs” for organizations anxious to leverage its great promises in a post-pandemic, digital-first world.

June 10, 2021/by Andrew Humphreys

CMS selects winners in AI outcomes challenge

American Academy of Family Physicians (AAFP), Artificial Intelligence, Centers for Medicare and Medicaid Services (CMS), Clinicians, Departments, Health Outcomes, June 2021, Med Ad News

The Centers for Medicare & Medicaid Services (CMS) announced that ClosedLoop.ai was selected the winner and Geisinger the runner-up in the agency’s Artificial Intelligence Health Outcomes Challenge.

June 10, 2021/by Andrew Humphreys

Boehringer Ingelheim partners with Lifebit

Artificial Intelligence, Boehringer Ingelheim, Business, Infectious Diseases, Natural Language Processing (NLP), Outbreaks, Partnerships, Real world evidence, Research & Development, Researchers

Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.

June 9, 2021/by Andrew Humphreys

CytoReason and Ferring Using AI to Improve IBD Drug Options

Artificial Intelligence, Business, Collaborations, Drug Discovery, Human Body, Inflammatory Bowel Disease (IBD), Molecular Data

CytoReason and Ferring Pharmaceuticals announced a collaboration that pairs CytoReason’s artificial intelligence (AI)-based computational model of the human body with Ferring’s expertise in inflammatory bowel disease (IBD). The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.

May 26, 2021/by Andrew Humphreys

Klick Research: People Using Voice Technology for Medication Info Still Get the Most Accurate Results From Google Assistant

Artificial Intelligence, Brands, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Crisis, Data, Generics, Google, Marketing & Advertising, Medications, Siri, Studies, Voice Technology

New research from Klick Applied Sciences found that people using interactive voice technology for information on medications still get the most accurate results from Google Assistant. The data are especially relevant as consumers have increasingly been turning to these platforms during the pandemic.

May 19, 2021/by Andrew Humphreys

Bristol Myers Squibb Dives into AI Deal with Exscientia

Artificial Intelligence, Biopharma, Bristol Myers Squibb, Business, Collaborations, Deals, Licensing, Product Pipeline

One day after Bristol Myers Squibb announced a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Artificial Intelligence (AI)-focused biopharma company Exscientia that could hit $1.2 billion.

May 19, 2021/by Andrew Humphreys

The Road to Answers in Health Is Now a Multi-Lane Expressway

Artificial Intelligence, Consumers, Digital Health, Health, Machine Learning, Patients, Personal Health, Research, Studies

Finding more information about your personal health or the health of your family has never been more meaningful than over the past year. For many individuals, patients and consumers, the need to address myriad questions and seek out additional areas of interest has become a quest. But in an age when information is ubiquitous and public health is top of mind, a new study on health fluency indicates that the road to such insight is now paved with multiple lanes and involves more than the traditional health care organizations and companies relied on before.

April 27, 2021/by Andrew Humphreys

Q&A with Acting FDA Commissioner Janet Woodcock

Active Pharmaceutical Ingredients, Artificial Intelligence, Data, Diversity, FDA, FDA Commissioner, Health Technology, Pandemics, R&D

Acting FDA Commissioner Janet Woodcock shared her thoughts on pandemic issues and outlined FDA modernization plans in a Q&A session with the Alliance for a Stronger FDA..

April 19, 2021/by Andrew Humphreys

Relay Therapeutics Snaps up ZebiAI

Acquisitions, Business, Collaborations, Drug Discovery, Genetic Diseases, Google, Machine Learning, Oncology, Partnerships, Precision Medicine, Small Molecules, Stockholders

In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.

April 16, 2021/by Andrew Humphreys

Mayo Clinic Launches Joint Ventures to Create and Commercialize AI Diagnostic Tools

Algorithms, Artificial Intelligence, Business, Clinicians, Diagnostic Tools, Financing, Health Technology, Joint Ventures, Launches, Mayo Clinic, Medical Devices, Series A

Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.

April 14, 2021/by Andrew Humphreys